TrialInternational journal of rheumatic diseases2018

Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.

Zhanguo Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.